search
Back to results

Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves

Primary Purpose

Hearing Loss, Bilateral (Causes Other Than Tumors)

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Nucleus ABI541 Auditory Brainstem Implant
Sponsored by
NYU Langone Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hearing Loss, Bilateral (Causes Other Than Tumors) focused on measuring Auditory Brainstem Implant, Deafness, Hearing Loss, ABI

Eligibility Criteria

18 Months - 21 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Group 1: Prelinguistic hearing loss (birth-5 years; age at implantation of ABI 18 months-5 years)

• Pre-linguistic hearing loss (birth-5 yrs.; age at ABI 18 months-5yrs) with both:

  • MRI +/- CT evidence of one of the following:

    • Cochlear nerve deficiency
    • Cochlear aplasia or severe hypoplasia
    • Severe inner ear malformation
    • Post-meningitis ossification
  • When a cochlea is present or patent, lack of significant benefit from CI despite consistent use (>6 mo.)

    • No or limited speech perception ability (limited to pattern perception on closed set testing materials using the CI)
    • Lack of progress in auditory skills development

Group 2: Post-linguistic hearing loss (<21 yrs. of age)

  • Post-linguistic hearing loss (<21 yrs. of age) with:

    • Loss or lack of benefit from appropriate CI without the possibility for revision or contralateral implantation. Examples might include:

      • Post-meningitis ossification
      • Bilateral temporal bone fractures with cochlear nerve avulsion
      • Failed revision CI without benefit
    • Previously developed open set speech perception and auditory-oral language skills
  • No medical contraindications
  • Willing to receive the appropriate meningitis vaccinations
  • No or limited cognitive/developmental delays.
  • Strong family support
  • Reasonable expectations from parents/guardians including a thorough understanding:

    • of potential benefits and limitations of ABI
    • of parental role in rehabilitation
    • that the child may not develop spoken language as a primary communication mode or even sufficient spoken language to make significant academic progress in an aural/oral environment
  • Involvement in a rehabilitation program that emphasizes development of auditory skills with or without the use of supplementary visual communication.
  • Able to comply with study requirements including travel to investigation sites.
  • Informed consent for the procedure from the child's parents/legal guardian.

Exclusion Criteria:

For both Groups 1 and 2:

  • Pre- or post-linguistic child currently making significant progress with CI Even for the very young children (18 months of age with 6 months of use), nearly all children with a good auditory signal from their CI will show evidence of improvement in these metrics over time.
  • MRI evidence of one of the following:

    • normal cochlea and cochlear nerves or NF2
    • brainstem or cortical anomaly that makes implantation unfeasible
  • Clear surgical reason for poor CI performance that can be remediated with revision CI or contralateral surgery rather than ABI.
  • Intractable seizures or progressive, deteriorating neurological disorder
  • Patients with evidence of Chiari malformation, hydrocephalus, spina bifid a
  • Patients with any foreseeable need for a future MRI scan
  • Unable to participate in behavioral testing and mapping with their CI. If this appears to be an age effect, ABI will be delayed until we can be assured that the child will be able to participate, as reliable objective measures of mapping are currently not available for mapping these devices.
  • Unable to tolerate general anesthesia (cardiac, pulmonary, bleeding diathesis, etc.).
  • Need for brainstem irradiation
  • Unrealistic expectations on the part of the subject/family regarding the possible benefits, risks and limitations inherent to the procedure and ABI device.
  • Unwilling to sign the informed consent.
  • Unwilling to make necessary follow-up appointments.

Sites / Locations

  • NYU Cochlear Implant CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Pre-lingual Deafness

Post-Lingual Deafness

Arm Description

Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant in prelingiustically deaf children ages 18 months - 5 years

Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant in postlinguistically deaf children < 21 years of age

Outcomes

Primary Outcome Measures

ABI Device Complications
Study participants will be monitored on a case-by-case basis for ongoing or unanticipated medical complications. Adverse events will be tracked on a case-by-case basis and recorded at the time of occurrence and followed up at resolution. Any adverse events will be reported to the NYUSOM IRB. Should there be concern for the safety of the subjects because of their participation in the study by the investigators or the IRB, the study would be halted at least temporarily and a detailed discussion with the investigators and the IRB would be undertaken.

Secondary Outcome Measures

Audiologic Performance with ABI (Hearing, Speech and Language Assessments)
The following audiometry and speech perception tests will be administered as age-appropriate: Detection audiogram, aided and unaided individual ears IT-MAIS or MAIS LING 6 sound test ESP Low Verbal or Standard- MLV @ 50dB HL PB-k words and phonemes- MLV @ 50dB HL MLNT- recorded @ 60dB SPL LNT- recorded @ 60dB SPL HINT-C- 2 lists of 10 @ 60dB SPL CNC- 50 words @ 60dB SPL Each child will receive speech/language intervention using the Comprehensive Assessment of Spoken Language (CASL, Elizabeth Carrow-Woolfolk, 1999) The following tests will be administered when appropriate: The Oral and Written Language Scales (OWLS) Goldman-Fristoe Test of Articulation The Peabody Picture Vocabulary Test (PPVT) The Rossetti Infant-Toddler Language Scale Pre-School Language Scale, (PLS-5) The Expressive Vocabulary Test, 2nd Ed The Peabody Picture Vocabulary Test, 4th Ed

Full Information

First Posted
November 28, 2014
Last Updated
March 27, 2023
Sponsor
NYU Langone Health
search

1. Study Identification

Unique Protocol Identification Number
NCT02310399
Brief Title
Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves
Official Title
Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 2014 (Actual)
Primary Completion Date
May 1, 2025 (Anticipated)
Study Completion Date
May 1, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NYU Langone Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is a feasibility study of the Nucleus 24 ABI in children without NF2. It will be conducted as a repeated-measures, single subject experiment in order to accommodate the known variability in cochlear implant clinical results. Data obtained in the course of this study will be compared with the existing published outcome data from children with normal hearing and with cochlear implants (CIs). These comparisons may provide additional useful information about the progress of ABI subjects' performance over time. Also, this may allow the results of the current study to be utilized to design future pivotal studies of the device in the pediatric population.
Detailed Description
The purpose of this study is to evaluate the clinical safety and efficacy of the Nucleus™ 24 Auditory Brainstem Implant (ABI) in pediatric patients who do not have Neurofibromatosis Type 2 (NF2); specifically, children with total hearing loss due to severe cochlear anomalies, cochlear nerve disorders or failed cochlear implantation. These conditions can include: developmental or acquired cochlear nerve deficiency (CND), cochlear aplasia, post-meningitis cochlear ossification, or cochlear malformation. This study proposes to implant up to 10 pre-linguistic young children (18 mos to 5 yrs. of age) and up to 10 post-linguistic children (<21 yrs of age) with the Nucleus 24 Multichannel ABI in an attempt to demonstrate safety of the surgical procedure and device stimulation and the potential for auditory benefit beyond that experienced with a CI. These children would not qualify for the Nucleus ABI device, as their etiology is not an approved indication such as neurofibromatosis Type 2(NF2). Further, these children do not benefit from conventional hearing aids or cochlear implants. Two groups of children will be included: Group 1 will include prelingiustic deaf children ages 18 months - 5 years and Group 2 will include postlinguistic deaf children < 21 years of age. Post-operative evaluations will be conducted at the initial activation and at 1, 3, 6, 12, 18, 24, 30, and 36-month intervals post-activation in order to demonstrate the emergence of open-set speech perception abilities prior to study cessation. Experience in the CI literature has shown that a minimum of 2 years of device usage is required for children with pre-lingual hearing impairment to develop some open-set speech perception abilities. While Group 2 is post-linguistic and some may have had significant hearing prior to becoming deaf, the same time intervals will be used for consistency. Blinding or masking procedures are not included in the design, as the presence/absence of a brainstem implant cannot be easily concealed from the device recipients and/or clinical investigators.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hearing Loss, Bilateral (Causes Other Than Tumors)
Keywords
Auditory Brainstem Implant, Deafness, Hearing Loss, ABI

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Pre-lingual Deafness
Arm Type
Experimental
Arm Description
Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant in prelingiustically deaf children ages 18 months - 5 years
Arm Title
Post-Lingual Deafness
Arm Type
Experimental
Arm Description
Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant in postlinguistically deaf children < 21 years of age
Intervention Type
Device
Intervention Name(s)
Nucleus ABI541 Auditory Brainstem Implant
Intervention Description
Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant device
Primary Outcome Measure Information:
Title
ABI Device Complications
Description
Study participants will be monitored on a case-by-case basis for ongoing or unanticipated medical complications. Adverse events will be tracked on a case-by-case basis and recorded at the time of occurrence and followed up at resolution. Any adverse events will be reported to the NYUSOM IRB. Should there be concern for the safety of the subjects because of their participation in the study by the investigators or the IRB, the study would be halted at least temporarily and a detailed discussion with the investigators and the IRB would be undertaken.
Time Frame
5 Years from date of surgery
Secondary Outcome Measure Information:
Title
Audiologic Performance with ABI (Hearing, Speech and Language Assessments)
Description
The following audiometry and speech perception tests will be administered as age-appropriate: Detection audiogram, aided and unaided individual ears IT-MAIS or MAIS LING 6 sound test ESP Low Verbal or Standard- MLV @ 50dB HL PB-k words and phonemes- MLV @ 50dB HL MLNT- recorded @ 60dB SPL LNT- recorded @ 60dB SPL HINT-C- 2 lists of 10 @ 60dB SPL CNC- 50 words @ 60dB SPL Each child will receive speech/language intervention using the Comprehensive Assessment of Spoken Language (CASL, Elizabeth Carrow-Woolfolk, 1999) The following tests will be administered when appropriate: The Oral and Written Language Scales (OWLS) Goldman-Fristoe Test of Articulation The Peabody Picture Vocabulary Test (PPVT) The Rossetti Infant-Toddler Language Scale Pre-School Language Scale, (PLS-5) The Expressive Vocabulary Test, 2nd Ed The Peabody Picture Vocabulary Test, 4th Ed
Time Frame
36 months from date of surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Months
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Group 1: Prelinguistic hearing loss (birth-5 years; age at implantation of ABI 18 months-5 years) • Pre-linguistic hearing loss (birth-5 yrs.; age at ABI 18 months-5yrs) with both: MRI +/- CT evidence of one of the following: Cochlear nerve deficiency Cochlear aplasia or severe hypoplasia Severe inner ear malformation Post-meningitis ossification When a cochlea is present or patent, lack of significant benefit from CI despite consistent use (>6 mo.) No or limited speech perception ability (limited to pattern perception on closed set testing materials using the CI) Lack of progress in auditory skills development Group 2: Post-linguistic hearing loss (<21 yrs. of age) Post-linguistic hearing loss (<21 yrs. of age) with: Loss or lack of benefit from appropriate CI without the possibility for revision or contralateral implantation. Examples might include: Post-meningitis ossification Bilateral temporal bone fractures with cochlear nerve avulsion Failed revision CI without benefit Previously developed open set speech perception and auditory-oral language skills No medical contraindications Willing to receive the appropriate meningitis vaccinations No or limited cognitive/developmental delays. Strong family support Reasonable expectations from parents/guardians including a thorough understanding: of potential benefits and limitations of ABI of parental role in rehabilitation that the child may not develop spoken language as a primary communication mode or even sufficient spoken language to make significant academic progress in an aural/oral environment Involvement in a rehabilitation program that emphasizes development of auditory skills with or without the use of supplementary visual communication. Able to comply with study requirements including travel to investigation sites. Informed consent for the procedure from the child's parents/legal guardian. Exclusion Criteria: For both Groups 1 and 2: Pre- or post-linguistic child currently making significant progress with CI Even for the very young children (18 months of age with 6 months of use), nearly all children with a good auditory signal from their CI will show evidence of improvement in these metrics over time. MRI evidence of one of the following: normal cochlea and cochlear nerves or NF2 brainstem or cortical anomaly that makes implantation unfeasible Clear surgical reason for poor CI performance that can be remediated with revision CI or contralateral surgery rather than ABI. Intractable seizures or progressive, deteriorating neurological disorder Patients with evidence of Chiari malformation, hydrocephalus, spina bifid a Patients with any foreseeable need for a future MRI scan Unable to participate in behavioral testing and mapping with their CI. If this appears to be an age effect, ABI will be delayed until we can be assured that the child will be able to participate, as reliable objective measures of mapping are currently not available for mapping these devices. Unable to tolerate general anesthesia (cardiac, pulmonary, bleeding diathesis, etc.). Need for brainstem irradiation Unrealistic expectations on the part of the subject/family regarding the possible benefits, risks and limitations inherent to the procedure and ABI device. Unwilling to sign the informed consent. Unwilling to make necessary follow-up appointments.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Susan B Waltzman, PhD
Phone
212-263-8803
Email
susan.waltzman@nyumc.org
First Name & Middle Initial & Last Name or Official Title & Degree
Kristin Montella
Phone
2122638182
Email
km302@nyumc.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John T. Roland, Jr., MD
Organizational Affiliation
NYU Langone Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
NYU Cochlear Implant Center
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kristin Montella
Phone
212-263-8182
Email
km302@nyumc.org
First Name & Middle Initial & Last Name & Degree
John T. Roland, MD
First Name & Middle Initial & Last Name & Degree
Susan B. Waltzman, PhD

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
19546832
Citation
Colletti V, Shannon R, Carner M, Veronese S, Colletti L. Outcomes in nontumor adults fitted with the auditory brainstem implant: 10 years' experience. Otol Neurotol. 2009 Aug;30(5):614-8. doi: 10.1097/MAO.0b013e3181a864f2.
Results Reference
background
PubMed Identifier
18496153
Citation
Colletti L, Zoccante L. Nonverbal cognitive abilities and auditory performance in children fitted with auditory brainstem implants: preliminary report. Laryngoscope. 2008 Aug;118(8):1443-8. doi: 10.1097/MLG.0b013e318173a011.
Results Reference
background
PubMed Identifier
19704357
Citation
Sennaroglu L, Ziyal I, Atas A, Sennaroglu G, Yucel E, Sevinc S, Ekin MC, Sarac S, Atay G, Ozgen B, Ozcan OE, Belgin E, Colletti V, Turan E. Preliminary results of auditory brainstem implantation in prelingually deaf children with inner ear malformations including severe stenosis of the cochlear aperture and aplasia of the cochlear nerve. Otol Neurotol. 2009 Sep;30(6):708-15. doi: 10.1097/MAO.0b013e3181b07d41.
Results Reference
background
PubMed Identifier
22196501
Citation
Sennaroglu L, Ziyal I. Auditory brainstem implantation. Auris Nasus Larynx. 2012 Oct;39(5):439-50. doi: 10.1016/j.anl.2011.10.013. Epub 2011 Dec 22.
Results Reference
background
PubMed Identifier
25377987
Citation
Colletti L, Shannon RV, Colletti V. The development of auditory perception in children after auditory brainstem implantation. Audiol Neurootol. 2014;19(6):386-94. doi: 10.1159/000363684. Epub 2014 Nov 4.
Results Reference
background
PubMed Identifier
24294682
Citation
Colletti L, Wilkinson EP, Colletti V. Auditory brainstem implantation after unsuccessful cochlear implantation of children with clinical diagnosis of cochlear nerve deficiency. Ann Otol Rhinol Laryngol. 2013 Oct;122(10):605-12.
Results Reference
background
Links:
URL
http://cochlear.med.nyu.edu/
Description
NYU Cochlear Implant Center homepage

Learn more about this trial

Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves

We'll reach out to this number within 24 hrs